Association of PD‐L1 tumor proportion score ≥20% with early resistance to osimertinib in patients with EGFR ‐mutated NSCLC
Cancer Medicine · 2023
DOI: 10.1002/cam4.6405 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2023. Verfasst von Yusuke Hamakawa und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Yokohama Municipal Citizen's Hospital, Kanagawa, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background The relationship between epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‐TKI) resistance, including osimertinib, and programmed cell death‐ligand 1 (PD‐L1) expression status in EGFR ‐mutated non‐small cell lung carcinoma (NSCLC) remains unclear. Patients and Methods We retrospectively analyzed 64 patients with unresectable advanced or metastatic NSCLC carrying EGFR exon 19 deletions (ex19del) or EGFR exon 21 L858R substitutions (L858R) who received osimertinib as the first‐line treatment. We compared progression‐free survival (PFS) between eligible patients with PD‐L1 tumor proportion scores (TPS) ≥20% and PD‐L1 TPS
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory Medicine, Yokohama Municipal Citizen's Hospital, Kanagawa, Japan.
- Department of Biostatistics, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.
- Department of Pulmonology, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.
ORCID-Profile: Yusuke Hamakawa, Tsuneo Shimokawa
Zitieren
APA
Hamakawa, Y., Agemi, Y., Shiba, A., Ikeda, T., Higashi, Y., Aga, M., Miyazaki, K., Taniguchi, Y., Misumi, Y., Nakamura, Y., Shimokawa, T., Saigusa, Y., Kobayashi, N., Okamoto, H., & Kaneko, T. (2023). Association of PD‐L1 tumor proportion score ≥20% with early resistance to osimertinib in patients with EGFR ‐mutated NSCLC. Cancer Medicine. https://doi.org/10.1002/cam4.6405
Vancouver
Hamakawa Y, Agemi Y, Shiba A, Ikeda T, Higashi Y, Aga M, et al. Association of PD‐L1 tumor proportion score ≥20% with early resistance to osimertinib in patients with EGFR ‐mutated NSCLC. Cancer Medicine. 2023. doi:10.1002/cam4.6405
BibTeX
@article{Hamakawa2023,
author = {Hamakawa, Yusuke and Agemi, Yoko and Shiba, Aya and Ikeda, Toshiki and Higashi, Yuko and Aga, Masaharu and Miyazaki, Kazuhito and Taniguchi, Yuri and Misumi, Yuki and Nakamura, Yukiko and Shimokawa, Tsuneo and Saigusa, Yusuke and Kobayashi, Nobuaki and Okamoto, Hiroaki and Kaneko, Takeshi},
title = {Association of PD‐L1 tumor proportion score ≥20% with early resistance to osimertinib in patients with EGFR ‐mutated NSCLC},
journal = {Cancer Medicine},
year = {2023},
doi = {10.1002/cam4.6405}
}
EUVIMED